Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Condition:   Basal Cell Nevus Syndrome Intervention:   Drug: Patidegib Topical Gel, 2% Sponsor:   PellePharm, Inc. Not yet recruiting

Source: ClinicalTrials.gov - March 16, 2020 Category: Research Source Type: clinical trials